Avivagen (Avivagen) Debt-to-Asset : 26.47 (As of Jul. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Avivagen Debt-to-Asset?

Avivagen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $4.65 Mil. Avivagen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.83 Mil. Avivagen's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jul. 2023 was $0.21 Mil. Avivagen's debt to asset for the quarter that ended in Jul. 2023 was 26.47.

Avivagen Debt-to-Asset Historical Data

The historical data trend for Avivagen's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avivagen Debt-to-Asset Chart

Avivagen Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Debt-to-Asset

Get a 7-Day Free Trial

0.72

2.43

2.82

1.96

4.46

Avivagen Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Debt-to-Asset	Get a 7-Day Free Trial															3.49	4.46	11.28	20.83	26.47

Competitive Comparison of Avivagen's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avivagen's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Avivagen's Debt-to-Asset falls into.

Avivagen Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Avivagen's Debt-to-Asset for the fiscal year that ended in Oct. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.61	+	3.836)	/	0.997
	=	4.46

Avivagen's Debt-to-Asset for the quarter that ended in Jul. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.646	+	0.834)	/	0.207
	=	26.47

Avivagen (OTCPK:VIVXF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Avivagen Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Avivagen's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Avivagen (Avivagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avivagen Inc (OTCPK:VIVXF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

VIV:Canada

Address

100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6

Website

https://www.avivagen.com

Avivagen Inc is a Canadian-based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal's health defenses. The company's products are based on OxC-beta Technology. Its geographical segments include the Philippines, which is the key revenue driver; Mexico; Thailand; United States; Malaysia; Taiwan; Brazil; and others.